Company intelligence / Profile preview

Forbion Growth Opportunities Fund II

Naarden, Netherlands

Ownership: Private
Development stage: Other

Overview

Forbion Growth Opportunities Fund II focuses on investing in late-stage clinical assets, pre-IPO, or undervalued public life sciences companies, primarily in Europe and North America. It achieved a first close of €470m in 2022 towards a €600m hard cap. The fund targets investments of up to €70m per deal and has already seen five exits.

Industry: Investors

Partnerships

LonzaThermo Fisher ScientificCharles River Laboratories

Beyond the preview

Go deeper on Forbion Growth Opportunities Fund II.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forbion Growth Opportunities Fund II.

Explore the full profile